Nitrate administration prior to percutaneous coronary intervention (PCI) may decrease patients’ risk of contrast-induced nephropathy (CIN), according to the findings of a retrospective single-center study.
Julio G. Peguero, MD, and colleagues at the Mount Sinai Heart Institute in Miami Beach reviewed data from 199 patients who underwent PCI. The researchers compared post-procedure renal function between 112 patients who received nitrates prior to PCI and 87 who did not. The two groups were similar with respect to baseline characteristics. The investigators defined CIN as a 25% or 0.5 mg/dL or greater increase in serum creatinine during the first 48-72 hours after contrast exposure.
CIN developed in 15.2% of patients who received nitrates compared with 29.9% of those who did not, a significant difference between the groups, the investigators reported online ahead of print in the Journal of Cardiovascular Pharmacology and Therapeutics. Further analysis showed that nitrate use was independently associated with a significant 67% reduced risk of CIN. Of the various methods of nitrate administration, intravenous infusion was the most efficacious way to prevent CIN, according to the researchers.